Vuba aha, umurwayi urwaye kanseri y’agahinda ka pancreas wari warananiwe kuvurwa inshuro nyinshi mbere yagabanutse ikibyimba nyuma yo guhabwa ubuvuzi bwa KD-496 CAR-T cell therapy, byemejwe ko azakomeza kumererwa neza nyuma y’iminsi 180 nyuma yo kuvurwa.
Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.
Nimero ya Terefone: 4008803716
Indangamuntu ya WeChat: 17801183037
Imeri:myimmnet@163.com
Uyu murwayi, umugore w'imyaka 73, yasuzumwe muri Nyakanga 2021 afite umutwe wa pancreas urimo kuziba kw'imiyoboro y'amaraso make. Yakorewe isuzuma rya duodenectomy, aho habonetse uburemere bukomeye bwa cm 3 mu gihe umutwe wa pancreas uncinate. Isuzuma ry'indwara ryemeza ko adenocarcinoma yari ifite itandukaniro riciriritse. Nyuma yo kubagwa, yahawe paclitaxel (nab-paclitaxel) ivanze na chimiotherapie ya S-1, hagakurikiraho M108 + nab-paclitaxel + gemcitabine na LM108 ivanze na toripalimab. Yari afite amateka yo kurwara schizophrenia na diyabete, byombi bigenzurwa neza n'imiti.
Muri Gashyantare 2025, umurwayi yahawe selile za KD-496 CAR-T. Mu isuzuma rya mbere rya kanseri nyuma y'ibyumweru bine, nubwo yari ageze mu zabukuru kandi afite umutwaro munini w'ikibyimba (ikibyimba cy'ibanze cya mm 58), ikibyimba cyari cyaragabanutseho 34.5% ugereranije n'icya mbere. Ku munsi wa 60, ikibyimba cyari cyaragabanutseho 37.9%, naho ku munsi wa 90 na 180, ikibyimba cyakomeje kugabanukaho 44.8%, kigumana igisubizo cy'igice (PR) nta burozi bukabije mu gifu cyangwa mu bwonko.
Umurwayi w’imyaka 70 wa kanseri y’igifu yabazwe muri Gashyantare 2023, nyuma yo kubagwa agaragaza ko afite adenocarcinoma y’igisebe yari imaze kwaguka kugeza ku nsoro za lymph, peritoneum, no mu bihaha byombi, hamwe n’indwara ya ascites na pleural effusion (indwara ikomeye kandi yanduye cyane). Nyuma y’ibyumweru umunani, yahawe SOX chemotherapy (oxaliplatin + S-1), ariko indwara ye yarakomeje. Nyuma yo kugerageza PX (paclitaxel) + PD-1 (immunotherapy) mu gihe cy’ingendo enye, hakurikiraho capecitabine + nivolumab, nabyo ntibyashoboye guhagarika gukomeza kwangirika. Amaherezo, nivolumab + fruquintinib (umuti urwanya angiogenic) yahawe, ariko nta ngaruka nziza ifite.
Ku munsi wa 28 wo kuvurwa na CAR-T, ikibyimba cyari cyaragabanutseho 47.3% ugereranije no kuvurwa mbere y’uko kivurwa, kibasha kugaragara neza mu buryo burambuye (PR). Ku munsi wa 60, ikibyimba cyakomeje kugabanukaho 41.9%, kigumana PR yemejwe, bigaragaza ko kidahinduka kandi gifite akamaro.
Umurwayi w’imyaka 55 wa kanseri y’igifu yaciwe gastroscopy radical gastrectomy mu Gushyingo 2023, indwara ya nyuma yo kubagwa igaragaza ko adenocarcinoma idasobanutse neza hamwe na carcinoma y’impeta y’urutoki (ifite ingaruka mbi cyane). Yagerageje imiti myinshi ya chimiotherapie + immunotherapy, harimo oxaliplatin + capecitabine + sintilimab, oxaliplatin + leucovorin + sintilimab, nab-paclitaxel + sintilimab + fruquintinib, na irinotecan monotherapy. Ariko, muri Gashyantare 2025, indwara ye yarushijeho kwiyongera, bituma ubuvuzi busanzwe budakora neza.
Hanyuma yahawe ubuvuzi bwa selile za CAR-T, kandi ku munsi wa 28, ikibyimba cyari cyaragabanutseho 31.8% ugereranije n’uko cyavuwe mbere y’uko kivurwa, kiba cyaragaragaje uburyo bwo kuvura igice (PR), kandi kurwanya indwara byagezweho neza.
Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.
Nimero ya Terefone: 4008803716
Indangamuntu ya WeChat: 17801183037
Imeri:myimmnet@163.com
Igihe cyo kohereza: 31 Nyakanga-2025